Kisqali monitoring?

What are the parameters for Kisqali monitoring?

Kisqali, also known as ribociclib, is a medication used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women. Monitoring of patients on Kisqali therapy is crucial to mitigate potential side effects and ensure the effectiveness of the treatment.

Why is frequent blood monitoring necessary for patients on Kisqali?

Frequent blood monitoring is necessary to check for potential toxicity related to Kisqali. Common laboratory abnormalities that have been reported in patients receiving Kisqali include neutropenia, anemia, thrombocytopenia, elevated liver enyzymes, and hyperglycemia [1]. Regular monitoring of blood counts is therefore essential to identify these abnormalities early and adjust the treatment plan as needed.

How is liver function monitored in patients receiving Kisqali?

Liver function monitoring is an essential aspect of Kisqali monitoring. Patients should have baseline liver function tests performed before starting treatment with Kisqali. During treatment, liver function tests should be performed periodically, including ALT (alanine aminotransferase), AST (aspartate aminotransferase), and bilirubin levels. Monitoring of liver function is important to identify potential liver toxicity, which can lead to dose modification or discontinuation of the medication [2].

What other parameters are monitored in patients on Kisqali therapy?

In addition to blood count and liver function monitoring, patients on Kisqali therapy should also have their renal function, electrolytes, and glucose levels monitored regularly. Renal function should be monitored by assessing serum creatinine levels, and electrolytes should be monitored to identify potential electrolyte imbalances. Hyperglycemia should be monitored to identify patients at risk of developing diabetes [3].

When should patients on Kisqali therapy seek medical attention?

Patients on Kisqali therapy should seek medical attention immediately if they experience any of the following symptoms: severe neutropenia, thrombocytopenia, or anemia; jaundice or hyperbilirubinemia; confusion, disorientation, or altered mental status; or severe hyperglycemia with symptoms of dehydration [4].

References

[1] DrugPatentWatch.com. (n.d.). Kisqali. Retrieved from https://www.drugpatentwatch.com/medicament/1660/kisqali-ribociclib

[2] NHS. (n.d.). Kisqali (ribociclib). Retrieved from https://www.nhs.uk/medicines/kisqali-ribociclib/

[3] FDA. (n.d.). Kisqali (ribociclib) tablets. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2017/208465s000lbl.pdf

[4] NCCN. (n.d.). Kisqali (ribociclib). Retrieved from https://www.nccn.org/professionals/physiciangls/default.aspx#breast